Creative Biolabs’ technical experts have successfully established the proprietary complement therapeutics system. We are looking forward to designing a strategy to carry on the therapeutic antibodies development services for our clients in complement therapeutic.
Complement Related Disease
The complement system is a central component of innate immunity and bridges the innate to the adaptive immune response. However, it can also turn its destructive capabilities against host cells and is involved in numerous diseases and pathological conditions. An imbalance in complement, either by insufficient or excessive complement activity, can have important pathological consequences. Antibody-based treatments can be employed to restore the balance in the complement network in order to achieve therapeutic effects. Complement inhibition can be beneficial in pathologies where the system is hyperactivated or where it is chronically activated and attacks or damages healthy tissues.
Following a general trend in the pharmaceutical industry, antibody-based therapeutics appears to be the most rapidly growing drug class against complement-related diseases. Crucial developments have done in their screening, production and humanization antibodies. By targeting specific components of the complement system, all stages from the initiation and activation process to single terminal actions can hypothetically be blocked in a selective manner.
Based on the advanced technology and rich experience, Creative Biolabs offers a comprehensive service of therapeutic antibodies development for our clients. Until now, our services including but not limited to:
C5 Antibody Development
As a key component of the complement system, C5 has been thoroughly studied in recent years. We provide antibody development services against the C5 target to meet your requirements. Here are two examples:
-
One of the antibodies can specifically bind to the terminal complement component 5, or C5, which acts at a late stage in the complement cascade. When activated, C5 is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. By inhibiting the complement cascade at this point, the normal, disease-preventing functions of the proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.
-
The other one is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system. The antibody is a humanized, monoclonal, single-chain antibody fragment that inhibits C5, thereby blocking its cleavage into active forms.
CD20 Antibody Development
We also provide antibody development services against the CD20 target. For example, an antibody has been developed as a human mAb that targets an epitope encompassing the membrane-proximal small-loop on the CD20 molecule, which differs from the binding location of rituximab. In vitro studies of this antibody have demonstrated that it is significantly more effective than rituximab at corresponding dose levels at lysing CLL cells and B-cell lines, especially those with low CD20 copy numbers.
Fig.1 Complement-dependent Cytotoxicity (CDC) and Antibody-dependent Cellular Cytotoxicity (ADCC) of Tumor Cells. (Kourtzelis & Rafail, 2016)
CD46 (MCP) Antibody Development
CD46, also known as membrane cofactor protein (MCP), acts as an inhibitory complement receptor to play the critical role in self-protection from the destructive action of autologous complement. Now, it has become an important target for therapeutic antibody exploration.
CD55 (DAF) Antibody Development
CD55, also known as decay-accelerating factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that inhibits both the classical and the alternative pathways of complement activation. It functions as a membrane-bound complement inhibitor to protect host cells from the destructive action of autologous complement.
CD59 (MIRL) Antibody Development
CD59 is also known as MAC-inhibitory protein (MAC-IP), membrane inhibitor of reactive lysis (MIRL), or protectin. It acts as an inhibitory complement receptor to protect host cells from self-destruction by complement-mediated lysis. Now, it has become a potential target for therapeutic antibody exploration.
If you are interested in using our therapeutic antibodies service to support your antibody discovery and development program, please contact us by sending us your detailed request through e-mail. A formal quote will be sent back to you soon.
Related Product
References
- Kourtzelis, I.; Rafail, S. The dual role of complement in cancer and its implication in anti-tumor therapy. Annals of translational medicine. 2016, 4(14).
For Research Use Only.
Related Sections:
